Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch to three different single tablet regimens (STRs) [tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV), TAF/FTC/elvitegravir/cobi (TAF/FTC/EVG/cobi) and ABC/lamivudine/dolutegravir (ABC/3TC/...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Andrea Giacomelli, Federico Conti, Laura Pezzati, Letizia Oreni, Anna Lisa Ridolfo, Valentina Morena, Cecilia Bonazzetti, Gabriele Pagani, Tiziana Formenti, Massimo Galli, Stefano Rusconi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-06-01
coleção:	BMC Infectious Diseases
Assuntos:	Single tablet regimens Tenofovir alafenamide Framingham score Cholesterol Cardiovascular risk Integrase inhibitors
Acesso em linha:	https://doi.org/10.1186/s12879-021-06304-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!